Summarized by Masters of Longevity from BioSpace - Funding.
Company will use funds to move Dualase into initial clinical biomarker proof-of-concept.
Key Takeaways
- Specific Biologics raised $35 million to fund Dualase clinical work.
- Dualase is designed to remove C9ORF72 repeat expansions precisely.
- Preclinical models showed repeat collapse but human efficacy remains unproven.
